What Pharma Companies Can Expect From the Influx of Humira Biosimilars

October 27

By Steve Callahan

Next year’s staggered launch of adalimumab biosimilars will mark one of the largest losses of exclusivity for a pharmaceutical company in U.S. market history.

For years, Humira has been the top-selling drug worldwide, raking in more than $20 billion in revenue last year. Manufacturers of reference biologics will be monitoring the impending upheaval, while companies with biosimilars in the pipeline will be eagerly tracking utilization data. Which drugs will secure a place on payers’ formularies, and when? And how will payers respond to this anticipated influx of Humira biosimilars?

To learn more, MMIT conducted a Rapid Response survey of 15 commercial payers representing 117 million covered lives. Most payers (53%) reported that they would likely make changes in their Humira contracting within the year, with several explaining that this transition represents a golden opportunity to recognize greater savings across the AbbVie portfolio.

For more findings and expert analysis, check out the full article on Drug Channels. And for more insight into how payers might cover and manage your drug, learn about the MMIT Strategic Launch Report.

0 Comments

Biosimilars |

Steve Callahan

Steve Callahan initially got his start conducting research in biology but transitioned his focus to Market Access as a consultant at firms such as Compass Strategic Consulting, Certara Evidence and Access, and IQVIA, and most recently as a senior manager leading market research for MMIT. Steve has conducted extensive research and has led a variety of projects within immunology and with biosimilars. Steve earned his B.S. in biology at Fairfield University, his M.S. in biology at Southern Connecticut State University, and his M.B.A. at the University of Connecticut.